Solving the Challenges of Selective Muscle Targeting
Motric Bio is advancing a new approach to treating movement disorders that targets the contractile protein in fast-twitch skeletal muscle – myosin 2. Direct myosin inhibition in skeletal muscle has been a challenging area for drug developers because of the presence of structurally similar myosins in other muscle types, including cardiac muscle in the heart.
Our lead product candidate, MTR-601, represents a scientific advance that overcomes the challenges of selective targeting of myosin-2. In developing MTR-601, we have identified a single amino acid protein (L476) where the fast-twitch skeletal myosin-2 differs from all other myosin-2 isoforms in the body. Identifying this key variation enables MTR-601 to be designed with a unique mechanism of action that specifically blocks fast-twitch skeletal muscle without affecting cardiac and smooth muscle types.
Skeletal striated muscle tissue